Bone marrow transplant consent: insight into patient motivations
Long-term follow-up: AML 17 trial of ATO and ATRA vs the standard of care in APL
Alan K. Burnett
How to generate an anticancer immune response in multiple myeloma
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
The road to individualized treatment for CLL